Pentixapharm Holding AG Stock
Price
Target price
€1.52
€1.52
-1.840%
-0.028
-1.840%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Financial data and news for Pentixapharm Holding
sharewise wants to provide you with the best news and tools for Pentixapharm Holding, so we directly link to the best financial data sources.
Financials
News
EQS-News: Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension
EQS-News: Pentixapharm Advances Regulatory Preparations for Phase 3 PANDA Study with Radiodiagnostic Candidate 68Ga-PentixaFor in Hypertension
EQS-News: Pentixapharm Publishes 9-Month Figures for 2025
EQS-News: Pentixapharm Publishes 9-Month Figures for 2025
EQS-News: Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
EQS-News: Pentixapharm to Report Third Quarter and First Nine Months 2025 Financial Results on Wednesday, November 12, 2025
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm significantly reduces projected loss for financial year 2025
EQS-News: Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
EQS-News: Pentixapharm Strengthens Pipeline Prioritization and Improves Cost Structure
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing Preclinical Activities
EQS-Adhoc: Pentixapharm Holding AG: Pentixapharm Focuses Development on Advanced Clinical Programs and Strengthens Financial Position by Discontinuing Preclinical Activities
EQS-News: Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
EQS-News: Pentixapharm Highlights Expanding CXCR4 Radiopharmaceutical Platform with New Clinical Findings at EANM 2025
EQS-News: Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial
EQS-News: Pentixapharm Announces Advancement of PentixaTher to Fourth Dose Level in Acute Myeloid Leukemia Trial